Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 4 of the 13 calendar months from Oct 2025 to Oct 2026: Nov 2025, Apr 2026, May 2026 and Jun 2026.
- Largest single sale: $1.1M (26,000 shares) of Travere Therapeutics, Inc. on Apr 14, 2026. Filing
- Last sale before this period: Feb 6, 2025.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Natera, Inc. (NTRA) | Director | Sep 18, 2018 | Jun 30, 2026 |
| Travere Therapeutics, Inc. (TVTX) | Director | Jul 26, 2016 | Jun 16, 2026 |
| Eikon Therapeutics, Inc. (EIKN) | Chief Medical Officer | Feb 4, 2026 | Mar 4, 2026 |
Also a director at
Recent filings
The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Jun 26, 2026, Natera, Inc.: 1,571 shares awarded; 75 shares granted. 1 filing: 1
- Jun 12, 2026, Travere Therapeutics, Inc.: sold 4,500 shares for $225K, under a disclosed plan; 4,500 shares acquired by exercising options. 1 filing: 1
- May 19, 2026, Travere Therapeutics, Inc.: 4,000 shares awarded. 1 filing: 1
- May 5, 2026, Travere Therapeutics, Inc.: sold 4,500 shares for $210K, under a disclosed plan; 4,500 shares acquired by exercising options. 1 filing: 1
- May 1, 2026, Travere Therapeutics, Inc.: sold 9,750 shares for $431K, under a disclosed plan; 9,750 shares acquired by exercising options. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.